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Purpose: The aim of this study was to evaluate the recent changes in the clinico-
pathologic features of prostate cancer in Korea and to compare these features with 
those of Western populations. Materials and Methods: We retrospectively re-
viewed the data of 1582 men undergoing radical prostatectomy for clinically local-
ized prostate cancer between 1995 and 2007 at 10 institutions in Korea for compari-
son with Western studies. The patients were divided into two groups in order to 
evaluate the recent clinicopathological changes in prostate cancer: Group 1 had sur-
gery between 1995 and 2003 (n=280) and Group 2 had surgery between 2004 and 
2007 (n=1302). The mean follow-up period was 24 months. Results: Group 1 had 
a higher prostate-specific antigen level than Group 2 (10.0 ng/mL vs. 7.5 ng/mL, re-
spectively; p<0.001) and a lower proportion of biopsy Gleason scores ≤6 (35.0% 
vs. 48.1%, respectively; p<0.001). The proportion of patients with clinical T1 stage 
was higher in Group 2 than in Group 1. Group 1 had a lower proportion of organ-
confined disease (59.6% vs. 68.6%; p<0.001) and a lower proportion of Gleason 
scores ≤6 (21.3% vs. 33.0%; p<0.001), compared to Group 2. However, the rela-
tively higher proportion of pathologic Gleason scores ≤6 in Group 2 was still lower 
than those of Western men, even though the proportion of organ-confined disease 
reached to that of Western series. Conclusion: Korean men with prostate cancer 
currently present better clinicopathologic parameters. However, in comparison, Ko-
rean men still show relatively worse pathologic Gleason scores than Western men.
Key Words:    Prostate neoplasms, prostatectomy, treatment outcome, ethnic groups
INTRODUCTION
Prostate cancer is known to be the most common male cancer and the second most 
common cause of cancer-related mortality in the Unites States.1,2 Several factors 
have been reported to be risk factors for prostate cancer. These factors include aging, Seok-Soo Byun, et al.
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tem, with histologic grading determined in accordance with 
the Gleason grading system.9 Beginning 6-8 weeks after 
radical prostatectomy, the prostate-specific antigen (PSA) 
level was measured every 3-6 months. Biochemical failure 
was defined as having a PSA concentration ≥0.2 ng/mL on 
two consecutive occasions after having achieved an unde-
tectable PSA level.10
Grouping
The incidence of prostate cancer in Korea is increasing, and 
the number of radical prostatectomies has increased, corre-
spondingly. Therefore, patients were divided into the follow-
ing two groups in order to evaluate the recent changes in 
characteristics of prostate cancer in Korea: Group 1 had sur-
gery between 1995 and 2003 (n=280) and Group 2 had sur-
gery between 2004 and 2007 (n=1302). The separation of the 
two groups was based on a previous study involving the char-
acteristics of prostate cancer in Korea.8 The pre-operative 
clinicopathological parameters and post-operative variables, 
such as age, PSA, clinical stage, biopsy Gleason score, patho-
logic stage, and final Gleason score were compared between 
the two groups. The mean follow-up period was 24 months 
(range, 1-98 months). The 2-year biochemical recurrence-free 
survival was compared between the two groups due to the 
relatively short follow-up period in Group 2.  
Comparison with Western populations
We chose the Cancer of the Prostate Strategic Urological 
Research Endeavor (CaPSURE) databases, Shared Equal 
Access Regional Cancer Hospital (SEARCH) databases and 
a large retrospective Western study to compare the clinico-
pathological features of prostate cancer patients undergoing 
radical prostatectomy in Korean and Western countries.11-13 
Statistical analysis
Using the Statistical Package for Social Sciences (SPSS) 
software, version 17.0 (SPSS Inc., Chicago, IL, USA), we 
tested the distribution of clinicopathologic parameters using 
chi-square and Student t-tests. A Kaplan-Meier survival 
curve was obtained and biochemical recurrence-free sur-
vival was compared using a log rank test. A p-value <0.05 
was set for determination of significance.
 
RESULTS
 
The final study comprised 1582 men (mean age, 65.0 years; 
race, and high-fat diets.1 Racial differences have been report-
ed to impact the incidence and behavior of prostate cancer.1,2 
Korea is one of the most rapidly aging countries in the 
world and the proportion of the population ≥65 years of age 
has increased from 5.1% in 1990 to 9.1% in 2005.3,4 Ac-
cordingly, the number of patients with prostate-related dis-
ease is increasing rapidly. 
The incidence of prostate cancer in 2007 was fifth among 
all malignancies in Korean men.5 Although its incidence in 
Korea is relatively lower than that of Western countries, e.g. 
United States (155.5 per 100000 person-years), the age ad-
justed incidence rates of prostate cancer in Korean accord-
ing to the Korean Cancer Registry System rapidly increased 
from 10.1 per 100000 person-years in 2002 to 20.0 per 
100000 person-years in 2007.2,5,6 The incidence of prostate 
cancer in Korea is increasing due to several reasons includ-
ing public awareness programs and life styles change.7 In-
terestingly, recent data has shown poor differentiation of 
prostate cancers in Korean men.8 However, it is not clear 
whether ethnic differences truly affect the clinicopathologi-
cal features of this cancer in Korea. 
This study was designed to evaluate the recent changes in 
clinicopathological features of prostate cancer in Korean 
men and to compare these presenting features with Western 
studies. 
MATERIALS AND METHODS
　　　
Study population and data collection
We retrospectively reviewed data from 1582 men who had 
undergone radical prostatectomy for clinically localized 
prostate cancer between 1995 and 2007 at 10 institutions in 
Korea. This study was approved by the Institutional Re-
view Board of Samsung Medical Center. Patients who had 
received hormonal therapy or radiotherapy before radical 
prostatectomy or those without sufficient pre-operative 
clinical or pathologic data were excluded from the analysis. 
Needle biopsy specimens were taken from 6 (10.9%), 8 
(8.4%), 10 (14.8%), and 12 cores (65.8%), and additional 
cores if suspicious lesions were detected therein. The 
pathologic data were reviewed again by a group of expert 
uropathologists. All of the pathology slides from the 
18-gauge needle biopsy specimens, as well as surgical 
prostate specimens, were re-evaluated at participating med-
ical centers. The clinical and pathologic stage was assigned 
according to the 2002 tumor-node-metastasis staging sys-Recent Changes of Korean Prostate Cancer
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Group 2 than in Group 1 and the proportion of low Gleason 
scores (≤6) was correspondingly higher in Group 2 (p= 
0.003 and p<0.001, respectively). The median PSA level de-
creased from 10.0 ng/mL in Group 1 to 7.5 ng/mL in Group 
2. Patients with a PSA level <10.0 ng/mL totaled 50.0% and 
66.1% of Group 1 and Group 2, respectively (p<0.001 by 
chi-square test).  
range, 38-85 years) with a median pre-operative serum 
PSA level of 9.0 ng/mL (range, 0.2-233.9 ng/mL) and a 
median biopsy Gleason score of 7. The pre-operative clini-
copathological characteristics are shown in Table 1 accord-
ing to each group. Group 2 (surgery between 2004 and 
2007) was comprised of older patients (p=0.002). The pro-
portion of patients with clinical T1 stage was higher in 
Table 1. Distribution of Pre-Operative Clinicopathological Parameters between the Two Groups
Group 1 (n=280) Group 2 (n=1302) p value
Age (mean±SD, range) 63.9±6.2 (40-79) 65.2±6.6 (38-85)     0.002*
Clinical stage
    T1 136 (48.6)   691 (53.1)   0.003
†
    T2 125 (44.6)   475 (36.5)
    ≥T3 15 (5.4) 127 (9.8)
    Unclassified   4 (1.4)     9 (0.7)
PSA (ng/mL)
    Median 10.0 7.5
    Mean±SD 16.0±21.6 12.0±15.5
    0-4.0 12 (4.38) 156 (12.0) <0.001
†
    4.1-10.0 126 (45.62) 704 (54.1)
    10.1-20.0   86 (30.66) 289 (22.2)
    >20.0   54 (19.34) 149 (11.4)
    Unclassified 2 (0.7)   4 (0.3)
Gleason score
    Median 7.0 7.0
    Mean±SD (range) 6.9±1.3 7.0±0.9
    ≤6   98 (35.0) 626 (48.1) <0.001
†
    7 114 (40.7) 496 (38.1)
    8-10   64 (22.9) 170 (13.6)
    Unclassified    5 (1.8) 10 (0.8)
    Total 280 (100) 1302 (100)
PSA, prostate specific antigen; SD, standard deviation. 
*p value by t-test.
†p value by chi-square test.
Table 2. Pathologic Characteristics of Radical Prostatectomies between the Two Groups
Group 1 (n=267) Group 2 (n=1282) p value
Pathologic stage
    T2 159 (59.6) 879 (68.6) <0.001
    T3a   54 (20.2) 268 (20.9)
    T3b   38 (14.2) 79 (6.2)
    T4   6 (2.2) 21 (1.6)
    N+ 10 (3.7) 35 (2.7)
Gleason score
    Median 7.0 7.0
    Mean±SD (range) 7.3±1.2 6.8±0.8 <0.001
    ≤6   57 (21.3) 423 (33.0)
    7 127 (47.6) 719 (56.1)
    8-10   83 (31.1) 140 (10.9)
SD, standard deviation; N+, lymph node metastasis. 
p value by chi-square test. Seok-Soo Byun, et al.
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ed better characteristics in terms of pathologic stage and 
histologic differentiation compared to Group 1 (Table 2). 
Survival analysis showed that the biochemical-recurrence 
free survival favored Group 2 (p<0.001, by log-rank test) 
(Fig. 1). The calculated actuarial biochemical failure-free 
survival rate at 2 years was 61.3% and 86.1% for Group 1 
and Group 2, respectively.
We compared our results with the clinicopathological pa-
rameters of Westerners collected in large-scale series includ-
ing the Prostate Strategic Urological Research Endeavor 
(CaPSURE) databases, SEARCH databases and a large ret-
rospective Western study.11-13 Western series showed young-
er age and lower PSA levels compared to the groups in our 
study (p<0.001). Also, biopsy Gleason scores in Western se-
ries showed much higher proportions of patients with Glea-
son score of 6 than Korean counterparts (p<0.001). Distribu-
tion of final pathologic stages was similar between patients 
in Group 2 of the present study and the SEARCH database 
(Caucasians and African Americans, p=0.08 and p=0.88, re-
spectively). However, Koreans demonstrated a higher pro-
portion of worse pathologic Gleason scores (Gleason score 
≥7, p<0.001) (Table 3). 
Pathologic data demonstrated that organ-confined disease 
increased from 59.6% in Group 1 to 68.6% in Group 2 
(p<0.001 by chi-square test) (Table 2). Patients with moder-
ately and poorly differentiated cancers (Gleason score ≥7) 
accounted for 78.7% and 67.0% of Group 1 and Group 2, 
respectively (p<0.001 by chi-square test). Group 2 present-
Fig. 1. Kaplan-Meier curve of biochemical recurrence-free survival be-
tween the two groups.
Table 3. Comparison of Clinicopathological Characteristics with Western Studies 
Studies SEARCH database CaPSURE database Johns Hopkins study Present study
p value
Race Caucasian  African 
American Caucasian African 
American
Caucasian (89.6%) 
African American
(6.5%)
Asian (Korean)
1st group    2nd group
Number 1014 338 1269 133 4091 280 1302    
Age (yrs)
    Mean±SD 63.8±6.7 61.8±6.7 N/A N/A 57.8±6.5 63.9±6.2 65.2±6.6 <0.05   
Preoperative PSA
    Mean±SD (ng/mL)     9.8±10.3   11.9±14.8 9.6±0.3 15.6±1.5   7.5±6.4   16.0±21.6   12.0±15.5 <0.05
Clinical stage (%) <0.05
    T1 35 48 21 24 72.6 48.6 53.1
    T2 64 52 76 70 27.4 44.6 36.5
    T3   1   0   3   6       0   5.4   9.8
Biopsy Gleason score (%)  <0.05
    2-6 67 71 80 77 80.2 35.0 48.1
    7 23 22 12 12 17.5 40.7 38.1
    8-10   9   6   7 11   2.3 22.9 13.6
Pathologic stage (%) <0.05
    pT2 68 71 N/A N/A  74.3 59.6 68.6
    pT3 29 27 24.2 27.1 27.1
    pT4   2   2 -   2.2   1.6
    N+   3   2   1.4   3.7   2.7
Pathologic Gleason score (%) <0.05
    2-6 54 52 N/A N/A 68.6 21.3 33.0
    7 36 39 26.9 47.6 56.1
    8-10 10   9   4.6 31.1 10.9
N/A, not available; SD, standard deviation; PSA, prostate-specific antigen; N+, lymph node metastasis; SEARCH, shared equal access regional cancer 
hospital; CaPSURE, cancer of the prostate strategic urological research endeavor.
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three ethnic groups demonstrated no statistical differences 
in disease-free survival. However, Song, et al.8 reported that 
prostate cancer in 604 Korean men exhibited poor differen-
tiation and was adversely related to prognosis after radical 
prostatectomy. A relatively higher proportion of high-grade 
cancers, irrespective of initial serum PSA concentrations or 
the clinical stage, may be responsible for the greater serum 
PSA level at the time of presentation and eventually result in 
a greater rate of PSA failure, even in those with pathologic 
organ-confined disease. They suggested poorer outcomes 
for prostate cancer in Korean men via a plausible mecha-
nism involving an increased incidence of prostate cancer 
and the lower serum testosterone levels in Asians.8,20-22 How-
ever, the relevance of serum testosterone level and profiles 
of prostate cancer is still controversial.23
In the present study, Group 2 had more organ-confined 
disease and a favorable histologic differentiation. These two 
features are important variables to predict outcomes of pros-
tate cancer. They provided Group 2 with improved short-
term biochemical recurrence free survival. However, the rel-
atively higher proportions of pathologic Gleason scores ≤6 
(33.0%) in Group 2 is still lower compared to western men 
(40.0-61.1%), even though the proportion of organ-confined 
disease reached to that of their western counterparts.24-26 
Notwithstanding, Korean men still present poorer outcomes 
because of relatively worse pathologic parameters com-
pared to western men. The exact mechanisms underlying 
poorer pathologic Gleason scores in the recently managed 
Korean men (Group 2) cannot be determined due to the 
limited data collected in this retrospective study. 
Comparing Group 1 with Group 2, we wondered what led 
to the better profiles of clinical and pathologic parameters in 
Group 2. First, Koreans are becoming more knowledgeable 
on prostate cancer through public awareness programs and 
an increased interest in health issues.18 Accordingly, a great-
er number of men visit hospitals to determine their prostate 
status even though they have no symptoms. Many Koreans 
perform health check-ups to identify underlying health 
problems and these generally cover PSA screening in Kore-
an men. This has led to earlier detection of prostate cancer 
in asymptomatic men. Second, the recent rapid increase in 
prostate cancer has piqued physicians’ interest in this dis-
ease and more physicians have begun testing PSA in their 
daily clinical activities. 
We expected to find poorer biochemical recurrence free 
survival compared to Western populations. And it was not 
easy to understand this difference completely through retro-
DISCUSSION
Several factors have been reported to serve as risk factors 
for prostate cancer; specifically, aging, family history, and a 
animal-protein rich diet are known to increase the risk of 
prostate cancer.1 African-American men have a tendency to 
contract this disease more often compared to Caucasian 
men; however, studies on ethnic differences as they relate 
to prostate cancer in Asians are scarce.13,14 The incidence of 
prostate cancer is most common in western countries where 
Asians comprise a lower proportion of the general popula-
tion. It is well-known that immigrant men from Japan in the 
United States have a higher incidence of prostate cancer 
compared to their counterparts in their native country.15,16 
Therefore, some environmental factors, such as a western-
ized diet (low in vegetables and high in fat and protein), 
may explain the higher incidence in these immigrant men. 
Some Asian countries have rapidly developed and lifestyles 
have been westernized. Korea is one such country and the 
incidence of prostate cancer is increasing rapidly. As afore-
mentioned, prostate cancer was the fifth most common can-
cer in Korea in 2007 and the most rapidly increasing cancer 
in Korean men according to the Korean Cancer Registry.5 
Each year, the Korean Urological Association releases data 
on the number of radical prostatectomies performed in resi-
dent-training centers in Korea. The number of prostatecto-
mies was reported to increase from 348 in 2002 to 2,123 in 
2007.17 The basis for this increase in incidence of prostate 
cancer included increased longevity, westernized lifestyle, 
easier access to medical facilities for the general population, 
and the launch of several public awareness programs.7,18 Be-
cause of this situation, a number of urologists are interested 
in the behavior of prostate cancer in Korean men compared 
to other ethnic groups. However, few studies have reported 
the role of ethnic differences in Asians in terms of risk fac-
tors and characteristics of prostate cancer. This study was 
performed to evaluate the characteristics of prostate cancer 
in Korean men and to compare the presenting features of 
prostate cancer in Korea with those of Western studies.
African-American patients have been reported to experi-
ence worse outcomes compared to Caucasian counterparts.14 
Cohen, et al.19 reported a shorter disease-free survival in 
2814 African-American men compared to other ethnicities 
in their analysis of the Surveillance, Epidemiology, and 
End Results Program-Medicare database, including 23353 
Caucasian, 480 Hispanic, and 566 Asian men. The latter Seok-Soo Byun, et al.
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rectal examination in Korean men: a nationwide multicenter study. 
Urology 2007;70:1109-12.
8. Song C, Ro JY, Lee MS, Hong SJ, Chung BH, Choi HY, et al. 
Prostate cancer in Korean men exhibits poor differentiation and is 
adversely related to prognosis after radical prostatectomy. Urology 
2006;68:820-4.
9. Epstein JI, Allsbrook WC Jr, Amin MB, Egevad LL; ISUP Grad-
ing Committee. The 2005 International Society of Urological Pa-
thology (ISUP) Consensus Conference on Gleason Grading of 
Prostatic Carcinoma. Am J Surg Pathol 2005;29:1228-42.
10. Freedland SJ, Sutter ME, Dorey F, Aronson WJ. Defining the ideal 
cutpoint for determining PSA recurrence after radical prostatecto-
my. Prostate-specific antigen. Urology 2003;61:365-9.
11. Grossfeld GD, Latini DM, Downs T, Lubeck DP, Mehta SS, Car-
roll PR. Is ethnicity an independent predictor of prostate cancer 
recurrence after radical prostatectomy? J Urol 2002;168:2510-5.
12. Freedland SJ, Amling CL, Dorey F, Kane CJ, Presti JC Jr, Terris 
MK, et al. Race as an outcome predictor after radical prostatecto-
my: results from the Shared Equal Access Regional Cancer Hos-
pital (SEARCH) database. Urology 2002;60:670-4.
13. Hernandez DJ, Nielsen ME, Han M, Partin AW. Contemporary 
evaluation of the D’amico risk classification of prostate cancer. 
Urology 2007;70:931-5.
14. Godley PA, Schenck AP, Amamoo MA, Schoenbach VJ, Peacock 
S, Manning M, et al. Racial differences in mortality among Medi-
care recipients after treatment for localized prostate cancer. J Natl 
Cancer Inst 2003;95:1702-10.
15. Haenszel W, Kurihara M. Studies of Japanese migrants. I. Mortal-
ity from cancer and other diseases among Japanese in the United 
States. J Natl Cancer Inst 1968;40:43-68.
16. Yu H, Harris RE, Gao YT, Gao R, Wynder EL. Comparative epi-
demiology of cancers of the colon, rectum, prostate and breast in 
Shanghai, China versus the United States. Int J Epidemiol 1991; 
20:76-81.
17. The Korean Urological Association. Data on statistics of manage-
ment in resident training hospital in the Korean Urological Asso-
ciation in the year 2007. Korean J Urol 2008;49:1171-2.
18. Song C, Ahn H, Lee MS, Park J, Kwon TG, Kim HJ, et al. Mass 
screening for prostate cancer in Korea: a population based study. J 
Urol 2008;180:1949-52.
19. Cohen JH, Schoenbach VJ, Kaufman JS, Talcott JA, Schenck AP, 
Peacock S, et al. Racial differences in clinical progression among 
Medicare recipients after treatment for localized prostate cancer 
(United States). Cancer Causes Control 2006;17:803-11.
20. van Houten ME, Gooren LJ. Differences in reproductive endocri-
nology between Asian men and Caucasian men--a literature re-
view. Asian J Androl 2000;2:13-20.
21. Wu AH, Whittemore AS, Kolonel LN, Stanczyk FZ, John EM, 
Gallagher RP, et al. Lifestyle determinants of 5alpha-reductase 
metabolites in older African-American, white, and Asian-Ameri-
can men. Cancer Epidemiol Biomarkers Prev 2001;10:533-8.
22. Hoffman MA, DeWolf WC, Morgentaler A. Is low serum free tes-
tosterone a marker for high grade prostate cancer? J Urol 2000; 
163:824-7.
23. Hsing AW, Chu LW, Stanczyk FZ. Androgen and prostate cancer: 
is the hypothesis dead? Cancer Epidemiol Biomarkers Prev 
2008;17:2525-30.
24. Roehl KA, Han M, Ramos CG, Antenor JA, Catalona WJ. Cancer 
progression and survival rates following anatomical radical retro-
pubic prostatectomy in 3,478 consecutive patients: long-term re-
spective series, several factors, including ethnic and environ-
mental differences, may have had an impact on our results. 
First of all, we should consider the relatively short follow-up 
period of Group 2 of our study as one limitation in our study. 
We would need a longer follow-up in order to compare long-
term Korean biochemical recurrence free and cancer-specific 
survivals with that those of Western populations.
There were several other limitations in this study. The 
retrospective nature of this study may have created a selec-
tion bias, which in turn could lead to interference with ac-
curate analysis of the characteristics of prostate cancer. The 
socioeconomic factors such as education and income could 
affect differences in disease progression among Asians, 
Caucasians and African Americans, but the lack of such 
data limited our evaluation thereof. The lack of central 
pathologic review was also a limitation in our study. 
In conclusion, Korean men with prostate cancer currently 
present better clinical and pathologic parameters than men in 
Western countries. However, the pathologic Gleason score of 
Korean men remained poor, which might be attributable to 
ethnic differences in the behavior of prostate cancer. 
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